Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon 25,000 MMS after acute pancreatitis with pancreatic exocrine insufficiency
2008-005993-12Phase 4Terminated
- Sponsor
- Solvay
- Start
- Mar 2009
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pancreatin in exocrine pancreatic insufficiency (EPI) (3 arms), sponsored by Solvay. Primary endpoint: Change in coefficient of fat absorption. Started Mar 2009; status: terminated.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2008-005993-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005993-12.